INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) Patent applications |
Patent application number | Title | Published |
20150353618 | Methods and Pharmaceutical Composition for the Preservation of Vascular Endothelial Cell Barrier Integrity - The invention relates to an ANGPTL4 polypeptide for use in the preservation of vascular endothelial cell barrier integrity and reduction in no-reflow phenomenon with myocardial infarction. | 12-10-2015 |
20150307622 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF BONE METASTASES - The present disclosure relates to methods and pharmaceutical compositions for the treatment of bone metastases. In particular, the present disclosure relates to an agent selected from the group consisting of an anti-ROB04 antibody, an anti-ROB04 aptamer, a ROB04 decoy polypeptide, an inhibitor of ROB04 expression for use in a method for preventing or treating bone meta-stases in a subject in need thereof. | 10-29-2015 |
20150307589 | PEPTIDIC ANTAGONISTS OF CLASS III SEMAPHORINS/NEUROPILINS COMPLEXES - The present invention concern a peptidic antagonist of class III semaphorins/neuropilins complexes comprising an amino acid sequence, which is derived from the transmembrane domain of a protein selected in the group consisting of neuropilin-1, neuropilin-2, plexin-A1, plexin-A2, plexin-A3, plexin-A4, Nr-CAM, L1-CAM, integrin Beta 1 and integrin beta 2, and including at least a GxxxG motif, eventually fused to an heterologous sequence; a nucleic acid encoding for said peptidic antagonist, a pharmaceutical composition comprising such a peptidic antagonist or a nucleic acid encoding thereof and uses thereof. | 10-29-2015 |
20150297573 | TPL2 KINASE INHIBITORS FOR PREVENTING OR TREATING DIABETES AND FOR PROMOTING Beta-CELL SURVIVAL - The present invention relates to the use of a Tpl2 kinase inhibitor for preventing treating diabetes and promoting β-cell survival and function in a number of applications. | 10-22-2015 |
20150290297 | IGFBP-3 DERIVATIVES AND USES THEREOF - The present invention provides polypeptide derivatives of IGFBP-3 that are resistant to proteolytic cleavage. These IGFBP-3 derivatives are useful in a variety of therapeutic and diagnostic applications. Also provided are pharmaceutical compositions and kits comprising such IGFBP-3 derivatives and methods for using these derivatives for the treatment of a variety of disorders. | 10-15-2015 |
20150259645 | METHOD FOR INDUCING IL-2-FREE PROLIFERATION OF GAMMA DELTA T CELLS - The present invention concerns a method of inducing IL-2-free proliferation of γδ T cells using a combination of a γδ T cell activator and IL-33 for use in therapy of infection, cancer, autoimmunity as well as other diseases. | 09-17-2015 |
20150224291 | Bioprinting Station, Assembly Comprising Such Bioprinting Station and Bioprinting Method - Bioprinting station ( | 08-13-2015 |
20150224129 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE PROPHYLACTIC TREATMENT OF BACTERIAL SUPERINFECTIONS POST-INFLUENZA WITH INVARIANT NKT CELL AGONISTS - The present invention relates to methods and pharmaceutical compositions for the prophylactic treatment of bacterial superinfections post-influenza with iNKT cell agonists. | 08-13-2015 |
20150133381 | METHODS FOR THE DIAGNOSIS AND THE TREATMENT OF FAMILIAL THORACIC AORTIC ANEURYSMS CAUSED BY TGFB2 LOSS OF FUNCTION MUTATIONS - The present invention relates to methods for the diagnosis and the treatment of familial thoracic aortic aneurysms caused by TGFB2 loss of function mutations. More particularly, the present invention relates to a method for determining whether a subject is predisposed to thoracic aortic aneurysms comprising detecting a TGFB2 loss of function mutation wherein the presence of the mutation indicated that the subject is predisposed to thoracic aortic aneurysms. The present invention also relates to a transforming growth factor beta-2 (TGF-β2) polypeptide for use in the prophylactic treatment of a subject who has been considered as predisposed to thoracic aortic aneurysms by the method of the invention (i.e. a subject having one TGB2 loss of function mutation according to the invention). | 05-14-2015 |
20150133322 | METHOD FOR THE DIAGNOSIS OF EARLY RHEUMATOID ARTHRITIS - The present invention relates to biomarkers that are specifically recognized by autoantibodies present in a biological of patients with Rheumatoid Arthritis (RA). The invention provides methods and kits using these biomarkers for the diagnosis of RA, in particular for the diagnosis of early RA. | 05-14-2015 |
20150132329 | NOVEL MELANOMA ANTIGEN PEPTIDE AND USES THEREOF - The present invention relates to a melanoma antigen peptide comprising the amino acids sequence selected in the group consisting of SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14 or SEQ ID NO: 15 or a function-conservative variant thereof. Moreover the invention also relates to a melanoma antigen peptide according to the invention for use in the prevention or the treatment of melanoma in patient. | 05-14-2015 |
20150126549 | Inhibitors of the PP1/GADD34 Complex for the Treatment of a Condition Requiring an Immunosuppressive Activity - The present invention relates to the general field of the treatment and prevention of diseases involving an inflammatory condition, namely sepsis or infectious or viral diseases as well as diseases requiring for the of treatment an immunosuppressive activity namely autoimmune diseases and graft rejection. | 05-07-2015 |
20150125868 | ASXL1 AS A NEW DIAGNOSTIC MARKER OF MYELOID NEOPLASMS - The present invention relates to a method for diagnosing a myeloid cancer in a subject, which comprises the step of analyzing a biological sample from said subject by determining the presence or the absence of a mutation in the ASXL1 (additional sex combs like 1) gene coding for the polypeptide having the sequence SEQ ID No 2. A kit for diagnosing myeloid cancer in a subject comprising at least one nucleic acid probe or oligonucleotide or at least one antibody, which can be used in a such a method. | 05-07-2015 |
20150118259 | 28 KDA GST PROTEINS FROM SCHISTOSOMA FOR THE USE THEREOF IN THE TREATMENT OF INFLAMMATORY AUTOIMMUNE DISEASES GENERATING A TH1 AND/OR TH17 RESPONSE - The present invention relates to a product selected from a protein, a fragment of the protein, a derived sequence and a homologous sequence of the protein, the protein including or being constituted by the 28 kDa glutathione S-transferase protein from a schistosome selected from | 04-30-2015 |
20150111951 | METHODS FOR THE TREATMENT OF LEBER CONGENITAL AMAUROSIS - The present invention relates to a method for treating a Leber congenital amaurosis in a patient harbouring the mutation c.2991+1655 A>G in the CEP290 gene, comprising the step of administering to said patient at least one antisense oligonucleotide complementary to nucleic acid sequence that is necessary for preventing splicing of the cryptic exon inserted into the mutant c.2291+1655 A>G CEP290 mRNA | 04-23-2015 |
20150076333 | Microscope for High Spatial Resolution Imaging a Structure of Interest in a Sample - A microscope for high spatial resolution imaging a structure of interest in a sample comprising a substance having a first state with first spectral properties and a second state with second spectral properties, the microscope comprising: an objective-lens assembly, a wave front modulating optical device adapted to spatially vary an intensity of a transfer light beam, a probe detector arranged to detect an optical measurement signal from a portion of the substance in the second state and placed in an area of the transfer light beam with an intensity adapted not to transfer the substance between the first and second states said microscope comprising a phase contrast microscopy system which includes an intensity detector arranged to detect an intensity of an illuminating light beam after said illuminating light beam has passed through the sample, the objective-lens assembly and the wave front modulating optical device. | 03-19-2015 |
20150064110 | CROSSLINKED POLYSACCHARIDE BEADS COMPRISING AN IMAGING AGENT - The present invention relates to a method for preparing beads comprising imaging agent. The present invention further provides beads highly useful for medical imaging. | 03-05-2015 |
20150044717 | DEVICES AND METHODS FOR OBSERVING EUKARYOTIC CELLS WITHOUT CELL WALL - The present invention relates to methods and devices for observing eukaryotic cells devoid of cell wall, in particular for observing the cytokinetic ring, the device comprising a plurality of wells suitable for containing only one single eukaryotic cell and characterized in that the dimensions of the wells constrain the cells into an oblong shape with a long axis parallel to the depth of the wells. | 02-12-2015 |
20150018543 | ANTI-INFECTIVE COMPOUNDS - The present invention relates to 4H-pyrido[1,2-a]pyrimidin-4-one compounds and their use in the treatment of bacterial infections, in particular Tuberculosis. | 01-15-2015 |
20150010485 | USE OF MICRORNA MOLECULES TO INFLUENCE SKIN PIGMENTATION - At least one microRNA selected from among hsa-miR-330, hsa-miR-7 and hsa-miR-137, the mature forms thereof, and the precursors thereof, for depigmenting the skin, and an in vitro method for identifying depigmenting compounds, which includes the steps of: a) placing at least one test compound in contact with a sample of melanocytes; b) measuring the expression or activity of at least one microRNA selected from among miR-330, miR-7 and miR-137, the mature forms thereof, and the precursors thereof, in the melanocytes; c) selecting the compounds for which at least 20% activation of the expression or of the activity of at least one of the microRNAs is measured in the melanocytes treated in a) by an element for comparing with the untreated melanocytes. | 01-08-2015 |
20140371092 | METHODS FOR ASSESSING ENDOMETRIAL RECEPTIVITY OF A PATIENT AFTER CONTROLLED OVARIAN HYPERSTIMULATION - The present invention relates to methods and kits for assessing the endometrial receptivity of a patient after controlled ovarian hyperstimulation. More particularly, the invention relates to a method for assessing the endometrial receptivity of a patient after controlled ovarian hyperstimulation, comprising a step consisting of measuring the expression level of at least one gene selected from fifteen genes in an endometrial biopsy sample obtained from said patient wherein said genes are FGFBP1, MUC20, TM-PRSS3, PRUNE2, HES2, MGST1, ERRFI1, EDN1, SLC17A7, MET, CPT1B, DCDC2, LRRC39, IL18RAP, and FOXP1. | 12-18-2014 |
20140363886 | METHOD FOR PREPARING INDUCED PARAXIAL MESODERM PROGENITOR (IPAM) CELLS AND THEIR USE - The present invention relates to an ex vivo method for preparing induced paraxial mesoderm progenitor (iPAM) cells, said method comprising the step of culturing pluripotent cells in an appropriate culture medium comprising an effective amount of an activator of the Wnt signaling pathway and an effective amount of an inhibitor of the Bone Morphogenetic Protein (BMP) signaling pathway. | 12-11-2014 |
20140356943 | Reprogrammation of Eukaryotic Cells with Engineered Microvesicles - The present invention relates to a non-genetic, detergent-free, bacteria-free method for reprogramming a eukaryotic cell, in particular for obtaining induced pluripotent stem cells (iPS), by using engineered microvesicles carrying at least one reprogramming transcription factor, wherein said engineered microvesicles are virus-free. | 12-04-2014 |
20140335093 | PD-1 Antibodies and PD-L1 Antibodies and Uses Thereof - The invention relates to PD-1 antibodies and PD-L1 antibodies and uses thereof. | 11-13-2014 |
20140322744 | CLONABLE TAG FOR CORRELATIVE LIGHT AND ELECTRON MICROSCOPY LABELING - The present invention relates to a new clonable label for Correlative Light and Electron Microscopy based on the combination of modified metallothionein and lanthanides. | 10-30-2014 |
20140309238 | FLUORALKYLCARBONYL-OXADIAZOLES - The present invention relates to compounds of Formula (I), wherein R1 is chosen among the following radicals: (II); (III); (IV), (V), (VI) (VII) and n=1 or 2 and m=1 or 2 with the proviso that m=2 when R1 is (VIII). The present invention also relates to the use thereof as drugs, more particularly in the treatment of mycobacterial infections and more particularly in the treatment of tuberculosis. | 10-16-2014 |
20140308275 | METHODS FOR DIAGNOSING AND TREATING MYHRE SYNDROME - The present invention relates to methods for diagnosing and treating Myhre Syndrome. The invention provides a method for diagnosing or predicting Myhre Syndrome, or a risk of Myhre Syndrome, in a subject, which method comprises detecting a mutation in SMAD4 gene, as compared to a control population, wherein the presence of said mutation is indicative of Myhre Syndrome or of a risk of Myhre Syndrome. The present invention also relates to an inhibitor of the SMAD4-mediated TGFβ/BMP signalling pathway for use in the treatment of Myhre Syndrome. | 10-16-2014 |
20140302041 | ANTI-AXL ANTIBODIES AND USES THEREOF - The present invention relates to anti-Axl antibodies and uses thereof in diagnostic and therapeutic methods. More particularly, the present invention relates to a monoclonal antibody having specificity for Axl comprising an heavy chain variable region comprising SEQ ID NO:2 in the H-CDR1 region, SEQ ID NO:3 in the H-CDR2 region and SEQ ID NO:4 in the H-CDR3 region; and a light chain variable region comprising SEQ ID NO: 6 in the L-CDR1 region, SEQ ID NO:7 in the L-CDR2 region and SEQ ID NO:8 in the L-CDR3 region. Said monoclonal antibody binds to the extracellular domain of Axl via, SEQ ID NO:9, SEQ ID NO: 10 and SEQ ID NO: 11. | 10-09-2014 |
20140296106 | METHODS FOR SCREENING SUBSTANCES CAPABLE OF MODULATING THE REPLICATION OF AN INFLUENZA VIRUS - The present invention relates to methods for screening substances capable of modulating the replication of an influenza virus. More particularly, the present invention relates to methods for screening a plurality of substances capable of modulating the replication of an influenza virus in a host cell comprising the step consisting of identifying a substance that modulates the specific interaction of a host cell protein with a viral protein required for viral replication as depicted in table 1 or identifying a substance that modulates the specific interaction of a first host cell protein as depicted in table 1 with a second host cell protein present in cellular network of the first host cell protein or identifying a substance that modulates the expression of a host cell protein as depicted in table 1, or identifying a substance that modulates the activity of a host cell protein as depicted in table 1 | 10-02-2014 |
20140242107 | Direct Protein Delivery with Engineered Microvesicles - The present invention relates to direct protein delivery with engineered micro vesicles. | 08-28-2014 |
20140234342 | NKP46-MEDIATED NK CELL TUNING - The present invention relates to compounds (e.g. antibodies) that specifically bind and inhibit NKp46. Such compounds are capable, when administered to a mammal, capable of increasing the frequency of reactive and/or active NK cells. The invention also relates to pharmaceutical composition and methods of using the antibodies and compositions to treat or prevent diseases, e.g. cancer, infection, autoimmune diseases, inflammatory diseases and the like. | 08-21-2014 |
20140221353 | Methods for Determining the Oncogenic Condition of Cell, Uses Thereof, and Methods for Treating Cancer - The invention relates to methods for detecting the oncogenic condition of cells, including step where the amount of the OCDO compound in said cells is measured, and to the uses thereof. The invention further relates to OCDO inhibitors for use in methods for treating cancer. | 08-07-2014 |
20140219925 | POLYMER PARTICLES OR NANO-VECTORS AND USE THEREOF AS A DRUG AND/OR DIAGNOSTIC AGENT - Novel polymer nanovectors or particles and use thereof as medication and/or diagnostic agents. | 08-07-2014 |
20140200269 | Combination of a Statin and a Taxane for the Treatment of Gastric Cancer - The present invention relates to a combination of (i) a statin, and (ii) a taxane, for simultaneous or sequential use in the treatment of a patient suffering from solid tumor, e.g. a gastric cancer. The present invention also provides a statin, for use in a method for enhancing sensitivity of a patient suffering from a solid tumor to a taxane. | 07-17-2014 |
20140200200 | Antagonists of CB1 Receptor - The invention relates to an antagonist of CB1 receptor for use in the treatment of a pathologic condition or disorder selected from the group consisting of bladder and gastrointestinal disorders; inflammatory diseases; cardiovascular diseases; nephropathies; glaucoma; spasticity; cancer; osteoporosis; metabolic disorders; obesity; addiction, dependence, abuse and relapse related disorders; psychiatric and neurological disorders; neurodegenerative disorders; autoimmune hepatitis and encephalitis; pain; reproductive disorders and skin inflammatory and fibrotic diseases. | 07-17-2014 |
20140199292 | COMPOSITIONS AND METHODS FOR INHIBITING TUMOR DEVELOPMENT CAUSED BY CHEMOTHERAPY INDUCED SENESCENCE - The present invention relates to products and compositions containing (i) a chemotherapeutic agent and (ii) at least an active compound chosen from CCL2 inhibitors, CCR2 inhibitors, NF-κB inhibitors, PARP-1 inhibitors and ATM inhibitors, as a combined preparation for simultaneous, separate or sequential use for inhibiting tumor development caused by tumor cell senescence induced by said chemotherapeutic agent. The invention also refers to a method for monitoring the response to a chemotherapeutic agent of a patient suffering from a cancer, and to a method for predicting the tumor size evolution and/or the onset of metastasis in a patient suffering from a cancer. | 07-17-2014 |
20140187595 | Methods and Compositions Comprising AMPK Activator (Metformin/Troglitazone) for the Treatment of Myotonic Dystrophy Type 1 (DM1) - The present invention relates to methods and compositions for the treatment of Myotonic Dystrophy type 1 (DM1) with an AMPK activator . | 07-03-2014 |
20140186845 | METHODS FOR DETERMINING THE EXPRESSION LEVEL OF A GENE OF INTEREST INCLUDING CORRECTION OF RT-QPCR DATA FOR GENOMIC DNA-DERIVED SIGNALS - The present invention relates to methods for determining the expression level of a gene of interest in a nucleic acid sample by RT-qPCR. More specifically, procedures for determining the impact of a gDNA contamination on the measured total signal have been developed allowing the correction of the signal originating from the above said gDNA. A further aspect of the invention refers to a mean by which the sensitivity qPCR primers toward gDNA can be determined. | 07-03-2014 |
20140186366 | METHOD FOR PREDICTING THE RISK OF DEVELOPING A COLONIC NEOPLASIA - The present invention relates to an in vitro method for determining whether a patient having hyperplastic polyps is at risk of developing a colonic neoplasia after resection of said hyperplastic polyps, said method comprising the step of determining the level of progastrin expression in a tissue sample of a hyperplastic polyp obtained from said patient. | 07-03-2014 |
20140140978 | POLYPEPTIDES ISOLATED FROM BREVIBACTERIUM AURANTIACUM AND THEIR USE FOR THE TREATMENT OF CANCER - The present invention relates to methods and pharmaceutical compositions for treating cancer. More specifically, the invention relates to a polypeptide isolated from | 05-22-2014 |
20140134728 | METHODS FOR ADJUSTING EXPRESSION OF MITOCHONDRIAL GENOME BY MICRORNA - The present invention relates to a method for adjusting the expression of the mitochondrial genome in a human cell comprising a step consisting of modulating the expression of a least one mi RNA selected from the group consisting of hsa-mi R-1973, hsa-mi R-1275, hsa-mi R-494, hsa-mi R-513a-5p, hsa-mi R-1246, hsa-mi R-328, hsa-mi R-1908, hsa-mi R-1972, hsa-mi R-1974, hsa-mi R-1977, hsa-mi R-638, hsa-mi R-1978 and hsa-mi R-1201. | 05-15-2014 |
20140134656 | METHOD FOR DETECTING THE PRESENCE OF CARBAPENEMASE-PRODUCING BACTERIA IN A SAMPLE - The present invention relates to a method for detecting the presence of carbapenemase-producing bacteria in a sample, said method comprising the steps of: a) performing cell lysis on a test sample in order to obtain an enzymatic suspension; b) reacting a fraction of the enzymatic suspension obtained in step a) with a reagent kit, said reagent kit comprising —a carbapenemase substrate selected from the group consisting of carbapenems and cephamycins, —a pH color indicator which will change color when the pH of the reaction mixture is comprised between 6.4 and 8.4, wherein a color change after step b) indicates the presence of carbapenemase-producing bacteria in the test sample. The invention also relates to a reagent kit, to a microtiter plate and to their uses in detecting the presence of carbapenemase producers in a test sample. | 05-15-2014 |
20140134632 | METHODS FOR DETERMINING DEVELOPMENTAL STAGE OF HUMAN CUMULUS CELLS - The present invention relates generally to the fields of reproductive medicine. More specifically, the present invention relates to a method determining the developmental stage of human cumulus cells issues from MII oocyte. | 05-15-2014 |
20140134102 | Fucoidans as Ligands for the Diagnosis of Degenerative Pathologies - The present invention relates to the diagnosis of clinical conditions characterized by undesirable and/or abnormal selectin expression. In particular, the invention provides for the use of fucoidans for the detection of selectins using imaging techniques including ultrasonography, scintigraphy and MRI. Selectin-targeted imaging agents are provided that comprise at least one fucoidan moiety associated with at least one detectable moiety. Methods and kits are described for using these imaging agents in the diagnosis of clinical conditions such as thrombosis, myocardial ischemia/reperfusion injury, stroke and ischemic brain trauma, neurodegenerative disorders, tumor metastasis and tumor growth, and rheumatoid arthritis. | 05-15-2014 |
20140127268 | Method for Expanding Monocytes - The invention relates to an ex vivo method for expanding monocytes, macrophages or dendritic cells, which method comprises inhibiting the expression or the activity of MafB and c-Maf in monocytes, macrophages or dendritic cells; and expanding the cells in the presence of at least one cytokine or an agonist of cytokine receptor signalling. | 05-08-2014 |
20140120572 | METHOD FOR DETERMINING A PLASMA VOLUME VARIATION AND DEVICES FOR IMPLEMENTING THE METHOD - Method for monitoring the evolution of heart failure in a patient comprising determining in vitro a physiological human parameter in a patient, comprising the steps consisting of: i) measuring values of two or more human parameters (P | 05-01-2014 |
20140120110 | ANGIOGENIC AND IMMUNOLOGIC APPLICATIONS OF ANTI-CD160 SPECIFIC COMPOUNDS OBTAINABLE FROM mAb CL1-R2 - The present invention relates to biological and medical applications of an anti-CD160 monoclonal antibody (CL1-R2 CNCM I-3204) and of the conservative equivalents thereof. It more particularly relates to the applications of these anti-CD160 compounds in the fields of EC angiogenesis, and NK and T cytokine production. | 05-01-2014 |
20140088290 | Novel Melanoma Antigen Peptide and Uses Thereof - The present invention relates to novel melanoma antigen peptides and specific T lymphocytes directed to said peptides and the use thereof for treating melanoma. | 03-27-2014 |
20140087387 | Methods for the Treatment, the Prognostic Assessment and the Staging of Non-Small Cell Lung Cancer - The present invention relates to methods for the treatment, the prognosis and the diagnosis of non-small cell lung cancer. | 03-27-2014 |
20140086923 | Antibodies Directed Against ICOS and Uses Thereof - The present invention provides antibodies directed against ICOS or a derivative thereof which neutralize ICOS engagement on Treg by inhibiting the fixation between ICOS and ICOS-L and abrogate proliferation of Treg induced by plasmacytoid dendritic cells. The present invention further provides antibodies directed against ICOS or a derivative thereof which induce IL-10 and IFNγ production, induce CD4+ T cells proliferation, reduce Tconv proliferation, and increase the immunosuppressive function of Treg. | 03-27-2014 |
20140073637 | AMINO-SUBSTITUTED-ALKYLOXY-BENZO[E]PYRIDO[4,3-B]INDOLE DERIVATIVES AS NEW POTENT KINASE INHIBITORS - The present invention relates to a new class of benzo[e]pyrido-indole, the amino-substituted-alkyloxy-benzo[e]pyrido[4,3-b]indole derivatives, having a particular kinase inhibition profile and useful as a therapeutic agent, in particular an anti-tumoral agent. | 03-13-2014 |
20140056932 | POLYNUCLEOTIDES ENCODING MHC CLASS I-RESTRICTED HTERT EPITOPES, ANALOGUES THEREOF OR POLYEPITOPES - This invention relates to the field of anticancer therapy, and to the identification of immunogenic peptides derived from the human telomerase reverse transcriptase (hTERT). The present invention relates to polynucleotides encoding hTERT epitopes restricted to MHC class I molecule, analogues thereof and polyepitopes containing such epitopes and/or analogues. Are also included in the present invention, vector and cell comprising such polynucleotides. The present invention also concerns composition comprising hTERT polypeptides, corresponding polynucleotides, vectors and cells, for use in the treatment and/or prevention of cancer. | 02-27-2014 |
20140030272 | Methods for Diagnosing and Treating Iron Dysregulation - The present invention relates to methods for diagnosing and treating iron overload and iron deficiency. | 01-30-2014 |
20140017707 | METHODS AND KITS FOR PREDICTING THE RISK OF RESPIRATORY FAILURE, RENAL FAILURE OR THROMBOPENIA IN A SEPTIC PATIENT BY MEASURING ENDOCAN LEVELS IN BLOOD - The present invention relates to methods and kits for predicting the risk of respiratory failure, renal failure or thrombopenia in a septic patient. More particularly, the present invention relates to a method for predicting the risk of having an organ failure selected from the group consisting of respiratory failure, renal failure and thrombopenia in a septic patient comprising a step consisting of measuring the concentration of endocan in a blood sample obtained from said septic patient. | 01-16-2014 |
20140005098 | IGFBP-3 DERIVATIVES AND USES THEREOF | 01-02-2014 |
20130225905 | DEVICE THAT IS IMPLANTABLE IN THE TEMPORAL BONE FOR DELIVERING A MATERIAL, AND HEARING AID PROVIDED WITH SUCH A DEVICE - A device that is implantable in the temporal bone for dispensing at least one component of a liquid product, comprising a catheter and means for moving the component along the catheter, wherein the product incorporates particles for transporting the component, the particles being movable under the effect of a magnetic field, wherein the catheter comprises portions for discharging the component from the catheter, the discharging portions being distributed along the catheter, and wherein the moving means comprise means for generating a magnetic field near each discharging portion so as to move the product from discharging portion to discharging portion, the field-generating means comprising windings that surround the discharging portions and that are connected to a control module designed to successively power at least some of the windings. | 08-29-2013 |
20130189259 | ANTI-GLYCOPROTEIN VI SCFV FRAGMENT FOR TREATMENT OF THROMBOSIS - The present invention relates to a single chain variable fragment (scFv 9O12.2) directed against human glycoprotein VI, constituted of the VH and VL domains of 9 O12.2.2 monoclonal antibody linked via a (Gly | 07-25-2013 |
20130183336 | Vaccine for Prophylaxis or Treatment of an Allergen-Driven Airway Pathology - The present invention relates to a life attenuated | 07-18-2013 |
20130178388 | Methods and Kits for the Diagnosis of Rheumatoid Arthritis - The present invention relates to the identification and use of proteins with clinical relevance to rheumatoid arthritis (RA). In particular, the invention provides the identity of marker proteins that specifically react with RA-associated autoantibodies. Also provided are methods, arrays and kits for using these proteins in the diagnosis of RA, and in the selection and/or monitoring of treatment regimens. | 07-11-2013 |
20130131024 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF FLUID ACCUMULATION IN AND/ OR UNDER THE RETINA - The present invention provides methods and compositions for the treatment of fluid accumulation in and/or under the retina. | 05-23-2013 |
20130129676 | COMBINATION OF ANTI-ENVELOPE ANTIBODIES AND ANTI-RECEPTOR ANTIBODIES FOR THE TREATMENT AND PREVENTION OF HCV INFECTION - The present invention provides combinations of antibodies for use in the treatment or the prevention of HCV infection. In particular, combinations are provided that comprise at least one anti-HCV envelope antibody and at least one anti-HCV receptor antibody, wherein the anti-HCV-envelope antibody and anti-HCV-receptor antibody act in a highly synergistic manner to inhibit HCV entry into susceptible cells. Also provided are pharmaceutical compositions and kits comprising such combinations and methods of using these compositions and kits for treating or preventing HCV infection. | 05-23-2013 |
20130122006 | ANTI-CD160 SPECIFIC ANTIBODIES FOR THE TREATMENT OF EYE DISORDERS BASED ON NEOANGIOGENESIS - The present invention relates to the use of at least one anti-CD 160 antibody, preferably a compound selected from CL1-R2 monoclonal antibody (which may be obtained by the hybridoma CNCM I-3204), its conservative fragments and its conservative derivatives, for preparing a drug designed to treat neovascular eye diseases. | 05-16-2013 |
20130095133 | PHARMACEUTICAL COMPOSITIONS COMPRISING A POLYPEPTIDE COMPRISING AT LEAST ONE CXXC MOTIF AND HETEROLOGOUS ANTIGENS AND USES THEREOF - The invention relates to pharmaceutical compositions using a polypeptide comprising at least one CXXC motif, such as | 04-18-2013 |
20130085169 | METHODS AND COMPOSITIONS COMPRISING AMPK ACTIVATOR (METFORMIN/TROGLITAZONE) FOR THE TREATMENT OF MYOTONIC DYSTROPHY TYPE 1 (DM1) - The present invention relates to methods and compositions for the treatment of Myotonic Dystrophy type 1 (DM1) with an AMPK activator . | 04-04-2013 |
20130052187 | Antibodies Directed Against Hepatitis C Virus E1E2 Complex, Compositions of HCV Particles, and Pharmaceutical Compositions - New conformational antibodies, and more particular conformational monoclonal antibodies and fragments thereof, are directed against HCV. Also provided are compositions of particles that are recognized by such antibodies, and pharmaceutical compositions containing these particles. Also described are HCV enveloped subviral particles and purified HCV enveloped complete viral particles, as well as processes for their preparation. | 02-28-2013 |
20120264146 | COMBINATION OF SPLA2 ACTIVITY AND LP(A) CARDIOVASCULAR RISK FACTORS FOR THE DIAGNOSIS/PROGNOSIS OF A CARDIOVASCULAR DISEASE/EVENT - The present invention related to a method of identifying a subject having or at risk of having or developing a cardiovascular disease and/or a cardiovascular event, comprising: -measuring, in a sample obtained from said subject, at least two cardiovascular risk factors: a) s PLA2 activity and b) Lipoprotein(a), -combining said measurements, the combined value of s PLA2 activity and Lp(a) being indicative of having or a risk of having or developing a cardiovascular disease and/or cardiovascular event. | 10-18-2012 |
20120245093 | Neuronal Viability Factor and Use Thereof - This invention relates to methods and compositions for detection and treatment of neurodegenerative diseases. In particular, the invention relates to polypeptides that can protect against neuron degeneration, nucleic acid molecules that encode such polypeptides, and antibodies that recognize said polypeptides. | 09-27-2012 |
20120226337 | Method and System for Treatment of a Body of a Mammal in Cardiac Arrest - Method for treatment of a body of a mammal in cardiac arrest, comprising the step of performing a therapeutic hypothermia of the body after the cardiac arrest has occurred, said therapeutic hypothermia comprising:
| 09-06-2012 |
20120225427 | sPLA2 IIA Polymorphism Analysis for the Diagnosis/Prognosis of a Cardiovascular Disease/Event - The invention relates to a method of identifying a subject having or at risk of having or developing a cardiovascular disease and/or a cardiovascular event, comprising determining, in a sample obtained from said subject, the presence or absence of a variant allele of nucleotide polymorphism (SNP) of the sPLA2 type IIA nucleic acid, wherein the SNP is selected from the group consisting of rs11573156 and rs2236771, wherein the presence of the minor allele (G) of SNP rs11573156 indicates an increased risk of having or being at risk of having or developing a cardiovascular disease and/or cardiovascular event, and the presence of the minor allele (C) of SNP rs2236771 indicates a decreased risk of having or being at risk of having or developing a cardiovascular disease and/or cardiovascular event. | 09-06-2012 |
20120207676 | NEUROTENSIN ANALOGUES FOR RADIOISOTOPE TARGETING TO NEUROTENSIN RECEPTOR-POSITIVE TUMORS - The invention relates to a new neurotensin analogue, or a salt thereof, useful for targeting to neurotensin receptor-positive tumors, like ductal pancreatic adenocarcinoma, exocrine pancreatic cancer, invasive ductal breast cancers, colon adeno-carcinoma, small cell lung carcinoma, Ewing sarcoma, meningioma, medulloblastoma and astrocytoma. | 08-16-2012 |
20120183475 | Fucoidans as Ligands for the Diagnosis of Degenerative Pathologies - The present invention relates to the diagnosis of clinical conditions characterized by undesirable and/or abnormal selectin expression. In particular, the invention provides for the use of fucoidans for the detection of selectins using imaging techniques including ultrasonography, scintigraphy and MRI. Selectin-targeted imaging agents are provided that comprise at least one fucoidan moiety associated with at least one detectable moiety. Methods and kits are described for using these imaging agents in the diagnosis of clinical conditions such as thrombosis, myocardial ischemia/reperfusion injury, stroke and ischemic brain trauma, neurodegenerative disorders, tumor metastasis and tumor growth, and rheumatoid arthritis. | 07-19-2012 |
20120177626 | HDL COMPRISING A THERAPEUTIC AGENT AND USE IN THERAPY - The present invention provides an HDL comprising an agent selected from the group consisting of antiproteases, antixoxidants, antimitotics, anti-apoptotic agents and agents involved in the iron metabolism for use as a medicament. | 07-12-2012 |
20120171705 | COMBINATION OF SPLA2 ACTIVITY AND OXPL/APOB CARDIOVASCULAR RISK FACTORS FOR THE DIAGNOSIS/PROGNOSIS OF A CARDIOVASCULAR DISEASE/EVENT - The use of a combination of sPLA2 activity and OxPL/apoB cardiovascular risk factors for the diagnosis/prognosis of a cardiovascular disease/event or for the monitoring of a cardiovascular disease. | 07-05-2012 |
20120165405 | Anaplerotic Therapy of Huntington Disease and Other Polyglutamine Diseases - The present invention relates to a method for treating and/or preventing Huntington disease and other polyglutamine diseases, comprising the step of administering an effective amount of a precursor of propionyl-CoA to an individual in need thereof. | 06-28-2012 |
20120165208 | METHOD FOR PREDICTING THE RESPONSIVENESS OF A PATIENT TO A TREATMENT WITH AN ANTI-CD20 ANTIBODY AND A METHOD FOR DIAGNOSING RHEUMATOID ARTHRITIS - The present invention relates to a method for predicting the responsiveness of a patient to a treatment with an anti-CD20 antibody, said method comprising measuring the level of miR-125b expression in a biological sample obtained from said patient. The present invention also relates to a method for diagnosing rheumatoid arthritis in a patient, said method comprising measuring the level of miR-125b expression in a biological sample obtained from said patient. | 06-28-2012 |
20120115171 | Method For Diagnosing Thrombophilia - The invention relates to a method for diagnosing thrombophilia in a subject suffering from HIV or from a systemic auto-immune disease, said method comprising determining in a blood sample obtained from said subject the level of free Protein S having Activated Protein C (APC) cofactor activity and the level of total Protein S. | 05-10-2012 |
20120100124 | METHODS FOR DETERMINING THE ONCOGENIC CONDITION OF CELL, USES THEREOF, AND METHODS FOR TREATING CANCER - The invention relates to methods for detecting the oncogenic condition of cells, including step where the amount of the OCDO compound in said cells is measured, and to the uses thereof. The invention further relates to OCDO inhibitors for use in methods for treating cancer. | 04-26-2012 |
20120093795 | COMPOUNDS TARGETING THE CATION-INDEPENDENT MANNOSE 6-PHOSPHATE RECEPTOR - The invention relates to conjugates of products of interest and of compounds targeting the cation-independent mannose 6-phosphate receptor with a high affinity. The invention also relates to their applications, for instance in enzyme replacement therapies. | 04-19-2012 |
20120093725 | Fucoidans as Ligands for the Diagnosis of Degenerative Pathologies - The present invention relates to the diagnosis of clinical conditions characterized by undesirable and/or abnormal selectin expression. In particular, the invention provides for the use of fucoidans for the detection of selectins using imaging techniques including ultrasonography, scintigraphy and MRI. Selectin-targeted imaging agents are provided that comprise at least one fucoidan moiety associated with at least one detectable moiety. Methods and kits are described for using these imaging agents in the diagnosis of clinical conditions such as thrombosis, myocardial ischemia/reperfusion injury, stroke and ischemic brain trauma, neurodegenerative disorders, tumor metastasis and tumor growth, and rheumatoid arthritis. | 04-19-2012 |
20120088259 | Post-Translation Modified Cardiac Troponin T As A Biomarker Of A Risk For Heart Failure - The present invention relates to methods and kits for the prediction of risk for heart failure using post-translation modified forms of cardiac troponin T as a biomarker. | 04-12-2012 |
20120064094 | Serotonin 5-HT3 Receptor Antagonists for Use in the Treatment of Lesional Vestibular Disorders - The invention relates to serotonin 5-HT3 receptor antagonists or inhibitors of serotonin 5-HT3 receptor gene expression for use in the treatment of a lesional vestibular disorder. | 03-15-2012 |
20120058110 | Method for Predicting the Responsiveness to an Anti-TNF Alpha Antibody Treatment - The present invention relates to a method for predicting the responsiveness of a patient to an anti-TNFα antibody treatment. | 03-08-2012 |
20120046181 | Biomarkers for the Diagnosis of Renal Allograft and Kidney Status - The present invention relates to the identification and use of protein biomarkers with clinical relevance to kidney status and chronic renal injury or disorder. In particular, the invention provides the identity of marker proteins which are recognized by antibodies present in patients suffering from end-stage renal disorder, stable renal transplant, renal transplant glomerulopathy (TG), and interstitial fibrosis and tubular atrophy (IFTA). Methods and kits are described for using these proteins in the study and diagnosis of chronic renal transplant injury, and in the selection and/or monitoring of treatment regimens. | 02-23-2012 |
20120015387 | MARKER PEPTIDES FOR DETERMINING THE OCCURRENCE OF AN INFLAMMATORY STATE IN A SUBJECT - An enzyme proteolysis-resistant peptide that binds to antibodies directed against the amino acid region 1-116 of the endocan's polypeptide sequence, which peptide possesses an apparent molecular weight of 14 kDa. | 01-19-2012 |
20120003224 | ANGIOGENIC AND IMMUNOLOGIC APPLICATIONS OF ANTI-CD160 SPECIFIC COMPOUNDS OBTAINABLE FROM mAb CL1-R2 - The present invention relates to biological and medical applications of an anti-CD160 monoclonal antibody (CL1-R2 CNCM I-3204) and of the conservative equivalents thereof. It more particularly relates to the applications of these anti-CD160 compounds in the fields of EC angiogenesis, and NK and T cytokine production. | 01-05-2012 |
20110256559 | Method for Detecting Soluble Amyloid Precursor Protein (APP) Alpha and/or Soluble APP Beta - The present invention relates to a method for detection or quantification of sAPPα and/or sAPPβ in a sample and their use for diagnosing and/or monitoring a neurodegenerative disease in a subject in need thereof and kit for use in said method. | 10-20-2011 |
20110244459 | METHODS FOR IDENTIFYING ERBB2 ALTERATION IN TUMORS - Methods for identifying ERBB2 (also named HER2) alteration in tumors, in particular cancer, based on the analysis of the expression of at least three genes of the ERBB2 amplicon located within less than one megabase on either side of ERBB2, and eventually of the gene corresponding to the Affymetrix probeset 234046_at (SEQ ID NO: 31), as well as a poynucleotide library useful for the molecular characterization of a cancer including polynucleotide sequences for detecting the genes, and a kit including the library. | 10-06-2011 |
20110236347 | Monoclonal Anti-Claudin 1 Antibodies for the Inhibition of Hepatitis C Virus Infection - The present invention provides monoclonal antibodies that specifically bind to the extracellular domain of human Claudin-1 on the cell surface, thereby inhibiting HCV entry into susceptible cells and preventing HCV infection of these cells; and hybridoma cell lines which produce such monoclonal antibodies. Also provided are reagents that comprise such antibodies, and pharmaceutical compositions comprising such antibodies. Methods of treating or preventing HCV infection by administration of an inventive monoclonal antibody, or a pharmaceutical composition thereof are also described. | 09-29-2011 |
20110218232 | Inhibitors of MRP4 and Agents Stimulating MRP4 Activity for the Treatment of Cardiac Disorders - The invention relates to inhibitors of Multi drug Resistant Protein 4 (MRP4) for the treatment and/or the prevention of cardiac disorders, such as acute or chronic heart failure and cardiogenic shock. The invention also relates to agents stimulating MRP4 activity for the treatment and/or the prevention of cardiac hypertrophy. | 09-08-2011 |
20110212098 | Novel Melanoma Antigen Peptide and Uses Thereof - The present invention relates to novel melanoma antigen peptides and specific T lymphocytes directed to said peptides and the use thereof for treating melanoma. | 09-01-2011 |
20110185441 | TRANSGENIC ANIMALS AND METHODS OF MAKING RECOMBINANT ANTIBODIES - The present invention describes a means for obtaining cells which produce human, humanized or chimeric antibodies in commercially useful quantities. The invention permits high antibody producer cells to be selected and isolated from animals for use in culture to produce antibodies. The invention also provides methods for the affinity maturation of human, humanized or chimeric immunoglobulins. | 07-28-2011 |
20110177970 | METHODS FOR PREDICTING OR MONITORING WHETHER A PATIENT AFFECTED BY A CANCER IS RESPONSIVE TO A TREATMENT WITH A MOLECULE OF THE TAXOID FAMILY - The present invention concerns in vitro methods for predicting or monitoring whether a patient affected by a cancer is responsive to a treatment with a molecule of the taxoid family based on a resistance expression signature, kits for performing the methods, and methods for screening or identifying a compound suitable for improving the treatment of a cancer with a molecule of the taxoid family or for reducing the resistance development during the treatment of a cancer with the molecule of the taxoid family. | 07-21-2011 |
20110166428 | NOVEL METHOD FOR MEASURING INSULIN RESISTANCE - Method of using at least one glucose derivative, halogenated in the 6 position, for the implementation of a process for the determination of insulin resistance in a mammal, in particular man, by measuring
| 07-07-2011 |
20110135661 | TREATMENT AND PREVENTION OF DRY AGE-RELATED MACULAR DEGENERATION BY ACTIVATING CD36 - The present invention relates to methods and compositions for the prevention and/or treatment of dry age-related macular degeneration by administering a CD 36-activator compound to a subject in need thereof; wherein the CD36 activator compound is the CD36 antibody FA6-152, or the growth hormone (GH)-releasing peptide family-derived compound EP80317 or the compound of Formula 1 [A-(Xaa) | 06-09-2011 |
20110104136 | Natural Killer p30 (NKp30) Dysfunction and the Biological Applications Thereof - The present invention relates to a method of assessing a favourable or, on the contrary, an unfavourable prognosis of a cancer in the subject, which method comprises detecting the presence of a mutated Natural Cytotoxicity-triggering Receptor 3 (NCR3) nucleic acid, an abnormal relative amount of at least one particular Natural Killer p30 (NKp30) RNA transcript isoform, and/or an abnormal Natural Killer p30 (NKp30) expression or activity of at least one particular NKp30 protein isoform in a sample from the subject, the presence of said mutated NCR3 nucleic acid, abnormal relative amount of at least one particular NKp30 RNA transcript isoform, or abnormal expression or activity of at least one particular NKp30 protein isoform being indicative of the prognosis of said cancer in the subject. | 05-05-2011 |
20110070242 | Methods for Diagnosing and Treating Iron Dysregulation - The present invention relates to methods for diagnosing and treating iron overload and iron deficiency. | 03-24-2011 |
20110070238 | CYTOTOXIC ANTI-LAG-3 MONOCLONAL ANTIBODY AND ITS USE IN THE TREATMENT OR PREVENTION OF ORGAN TRANSPLANT REJECTION AND AUTOIMMUNE DISEASE - Cytotoxic anti-LAG-3 monoclonal antibodies or fragments thereof causing depletion of LAG-3 | 03-24-2011 |
20110065609 | Methods and Kits for the Diagnosis of Rheumatoid Arthritis - The present invention relates to the identification and use of proteins with clinical relevance to rheumatoid arthritis (RA). In particular, the invention provides the identity of marker proteins that specifically react with RA-associated autoantibodies. Also provided are methods, arrays and kits for using these proteins in the diagnosis of RA, and in the selection and/or monitoring of treatment regimens. | 03-17-2011 |
20110044906 | Methods for the Treatment, the Prognostic Assessment and the Staging of Non-Small Cell Lung Cancer - The present invention relates to methods for the treatment, the prognosis and the diagnosis of non-small cell lung cancer. | 02-24-2011 |
20110028838 | Method and Apparatus for Measuring a Physical Parameter in Mammal Soft Tissues by Propagating Shear Waves - Method for measuring a physical parameter in soft tissues of a mammal, in which a mechanical shear wave is propagated through the soft tissues and observation of the propagation leads to determine values of a shear wave propagation parameter. The physical parameter is computed on the basis of these values. | 02-03-2011 |
20100316616 | Use of FZC18-Containing Collagen 18 Polypeptides for the Treatment, Diagnosis and Outcome Prediction of Diseases - The present invention relates to a polypeptide comprising at least 13 consecutive amino acids selected from the amino acid sequence as set forth in SEQ ID NO: 1 or a variant thereof comprising at least 70% identity over said 13 consecutive amino acids, wherein said polypeptide or variant thereof interacts with Wnt3a and can be used for the treatment of diseases associated with increased beta-catenin pathway activity. The present invention also relates to a method for detecting the presence of a disease associated with fibrogenesis and to a method for assessing the severity and/or predicting the outcome of cancer. | 12-16-2010 |
20100303828 | Antibodies Against Human CD39 and Use Thereof for Inhibiting T Regulatory Cells Activity - The invention relates to antibodies against human CD39 and use thereof for inhibiting T regulatory cells (Treg) activity. More particularly CD39 antibodies may be used for the treatment or prevention of cancers and infectious diseases. | 12-02-2010 |
20100284991 | Methods for the Treatment and Diagnosis of Bone Mineral Density Related Diseases - The present invention relates to methods of the treatment and diagnosis of bone mineral density related disorders. More particularly, the present invention relates to a method of diagnosing or predicting a bone mineral density related disease, or a risk of a bone mineral density related disease, in a subject, which method comprises detecting a mutation in the TBXAS1 gene, wherein the presence of said mutation is indicative of a bone mineral density related disease or of a risk of a bone mineral density related disease. The invention also relates to a compound selected in the group consisting of a thromboxane synthase (TXAS) encoding polynucleotide, a TXAS, thromboxane A2 or an analog thereof for treating or preventing a disease associated with an increased bone mineral density (e.g., Ghosal hematodiaphyseal dysplasia syndrome). The invention also relates to a compound selected from the group consisting of an inhibitor of TBXAS1 gene expression or a thromboxane inhibitor for treating or preventing a disease associated with a decreased bone mineral density (e.g., osteoporosis). | 11-11-2010 |
20100278809 | Inhibitors of MRP4 for the Treatment of Vascular Disorders - The invention relates to inhibitors of MRP4 for the treatment and/or the prevention of vascular disorders such as atherosclerosis, post-angioplasty restenosis, pulmonary arterial hypertension or vein-graft disease. | 11-04-2010 |
20100261654 | COMPOSITIONS AND METHODS FOR INCREASING VASCULARIZATION - Disclosed are methods of increasing vascularization in a tissue by administering a neublastin polypeptide to a mammal exhibiting impaired or inadequate blood flow in the tissue. The methods can be used to in the treatment or prevention of a disorder characterized by impaired or inadequate blood flow or to increase vascularization in an organ that has been transplanted into a subject. | 10-14-2010 |
20100210566 | AZAPEPTIDES AS CD36 BINDING COMPOUNDS - An azapeptide derivative of growth hormone releasing peptide (GHRP) of Formula I: A-(Xaa) | 08-19-2010 |
20100203575 | In Vitro Beating Heart Model - The invention relates to a method for preparing a heart organotypic slice culture, comprising; a) providing a slice of heart, b) placing the slice of step a) on the upper surface of a semiporous support which is permeable to a culture medium, c) placing the support of step b) onto a culture medium, the slice being fed through the semi-porous support by capillarity. | 08-12-2010 |
20100196921 | Method for Predicting the Outcome of a Critically Ill Patient - The present invention relates to a method for predicting the outcome of a critically ill patient, said method comprising measuring the concentration of Chromogranin A or a fragment thereof in a biological sample obtained from said patient. | 08-05-2010 |
20100196386 | LIGANDS OF HVEM FOR TREATING HEMATOLOGIC MALIGNANCIES AND AUTOIMMUNE DISEASES - The present invention relates to ligands of HVEM for the treatment of hematologic malignancies, in particular Chronic lymphocytic leukaemia, and for the treatment of autoimmune diseases. | 08-05-2010 |
20100184707 | ANTICONVULSIVE PHARMACEUTICAL COMPOSITIONS - The use of a substance selected from the group consisting of taurine, a taurine precursor, a taurine metabolite, a taurine derivative, a taurine analog and a substance required for the taurine biosynthesis, for manufacturing a pharmaceutical composition for preventing or inhibiting the undesirable side-effects caused to a human or an animal organism by an active ingredient that induces a high level of extracellular GABA or increases GABA receptor activation. | 07-22-2010 |
20100124555 | Compositions and Methods for Treating Pancreatic Tumors - The present invention relates to a method for producing an antigen-binding compound suitable for use in the treatment of cancer, the antigen-binding compounds and their uses. | 05-20-2010 |
20100113933 | CHIRP REVERSAL ULTRASOUND CONTRAST IMAGING - The invention relates to a method for detecting and imaging ultrasound echo signals returned from a target object comprising microbubbles, said microbubbles being characterized by a resonance frequency, said method comprising the steps of irradiating said target object with at least a first and second successive excitation signals, said first excitation signal being a sweep of increasing frequency with time, and said second excitation signal being a sweep of decreasing frequency with time, detecting echo signals of said first and second excitation signals from said target object, and, combining said echo signals. The maximum frequencies of said first and second excitation signals are lower than said resonance frequency. The invention also relates to an imaging apparatus. | 05-06-2010 |
20100112605 | Biomarker for the Medicine and the Biology of the Reproduction - The present invention relates to a new biomarker for the medicine and the biology of reproduction, in particular for in vitro fertilization (IVF) outcome. It relates to methods for predicting IVF outcome and for selecting the subject for IVF. | 05-06-2010 |
20100104581 | Methods for Diagnosing and Treating Graft Rejection and Inflammatory Conditions - The present invention relates to a method of diagnosis and/or prognosis of an inflammatory condition, which method comprises determining the expression level of TRIB1 in a biological sample of a patient, in particular in peripheral blood or in a biopsy of a diseased tissue. Methods for treating inflammatory conditions by modulating TRIB1 expression or activity are also described. | 04-29-2010 |
20100063147 | Anaplerotic Therapy of Huntington Disease and Other Polyglutamine Diseases - The present invention relates to a method for treating and/or preventing Huntington disease and other polyglutamine diseases, comprising the step of administering an effective amount of a precursor of propionyl-CoA to an individual in need thereof. | 03-11-2010 |
20100062987 | ANTICONVULSIVE PHARMACEUTICAL COMPOSITIONS - The present invention pertains to pharmaceutical compositions including, as the active ingredients, a combination of vigabatrin and of at least one glutamate receptor activating substance. | 03-11-2010 |
20100022504 | METHODS FOR TREATING LATENT TUBERCULOSIS - A method for treating individuals affected with latent tuberculosis comprising a step of administering an effective amount of one or more carbapenem compounds to the said individuals. | 01-28-2010 |
20100015653 | Compounds Regulating Calreticulin, KDEL Receptor and/or ERP-57 Cell Surface Exposure and Uses Thereof to Evaluate the Efficiency of a Cancer Treatment - The present invention relates to a method for determining the susceptibility of a patient tumour cell to a cancer treatment, which method comprises the detection or measure of CRT, KDEL receptor and/or ERp57 on the surface of a tumour cell. | 01-21-2010 |
20100008932 | USE OF SOLUBLE CD160 TO SUPPRESS IMMUNITY - Pharmaceutical composition including a soluble form of CD160 for treating an inflammatory condition involving an undesired immune response, such as tissue graft or organ rejection, and autoimmune diseases; in vitro method for screening an individual for the presence of an inflammatory condition such as infectious and autoimmune diseases, tissue graft and organ rejection, or the presence of a tumor or activated endothelial cells, or for monitoring therapy of an inflammatory condition such as an autoimmune disorder or a tissue or organ rejection, or a tumor during chemotherapy including treatment with an anti-angiogenic substance or antibody. | 01-14-2010 |
20100003272 | Method for Expanding Monocytes - The invention relates to an ex vivo method for expanding monocytes, macrophages or dendritic cells, which method comprises inhibiting the expression or the activity of MafB and c-Maf in monocytes, macrophages or dendritic cells; and expanding the cells in the presence of at least one cytokine or an agonist of cytokine receptor signaling. | 01-07-2010 |
20090318540 | NUCLEIC ACIDS FOR EXPRESSING A POLYNUCLEOTIDE OF INTEREST IN MAMMALIAN CANCER CELLS - The invention relates to regulatory polynucleotides derived (i) from rat and human AFP promoter sequences and (ii) from rat and human HIP/PAPI promoter sequences, which regulatory polynucleotides are useful for expressing nucleic acids of interest specifically in mammalian cancer cells, including mammalian cancer liver cells. | 12-24-2009 |
20090311714 | Methods for the Screening of Antibacterial Substances - The present invention concerns a method for the screening of antibacterial substances comprising a step of determining the ability of a candidate substance to inhibit the activity of a purified enzyme selected from the group consisting of: (i) a D-aspartate ligase comprising a polypeptide having an amino acid sequence possessing at least 50% amino acid identity with an amino acid sequence selected from the group consisting of SEQ ID No 1 to SEQ ID No 10, or a biologically active fragment thereof; and (ii) a L,D-transpeptidase comprising a polypeptide having an amino acid sequence possessing at least 50% amino acid identity with the amino acid sequence of SEQ ID No 11, or a biologically active fragment thereof. | 12-17-2009 |
20090305343 | Method For Expressing Polypeptides In Eukaryotic Cells Using Alternative Splicing - This invention relates to an expression cassette for expressing polypeptides in eukaryotic cells using alternative splicing. The expression cassette comprises in 5′ to 3′ downstream direction: a promoter; a sequence transcribed in a 5′ untranslated region (5′UTR); a donor splice site; an intron; a first acceptor splice site; a first cistron encoding a first polypeptide; a second acceptor splice site; a second cistron encoding a second polypeptide; an internal ribosome entry site (IRES) operably linked to a selection marker; and a sequence transcribed in a 3″ untranslated region (3′UTR) including a polyadenylation signal, wherein the polyadenylation signal is unique. | 12-10-2009 |
20090286689 | METHODS FOR ANALYZING DIFFERENTIAL GENE EXPRESSION ASSOCIATED WITH MYELOPROLIFERATIVE DISORDERS (MPD) CANCER DISEASE - The present application relates to gene analysis and, in particular, to gene expression profiling for identifying molecular signature of cancer disease, in particular the G1 phase of the cell cycle, such as myeloproliferative disorders (MPD) or breast cancer and studying cancer. | 11-19-2009 |
20090281461 | DEVICE AND METHOD FOR THE TIME-BASED ANALYSIS OF THE AGITATION OF A BEDRIDDEN PATIENT - Device for the time-based analysis of the agitation of a bedridden patient includes elements ( | 11-12-2009 |
20090252740 | Method for Predicting Responsiveness to TNF Alpha Blocking Agents - The invention provides an in vitro method for predicting whether a patient would be responsive to a treatment with a TNFα blocking agent, which method comprises determining the expression level of eight genes in a biological sample of said patient, wherein said genes are EPS15, HLA-DPB1, AKAP9, RASGRP3, MTCBP-1, PTNP12, MRPL22 and RPS28. The invention further provides a DNA chip for performing such method. | 10-08-2009 |
20090215053 | Vitro Method for the Prognosis of Progression of a Cancer and of the Outcome in a Patient and Means for Performing Said Method - The present invention relates to the prognosis of the outcome of a cancer in a patient, which prognosis is based on the quantification of one or several biological markers that are indicative of the presence of, or alternatively the level of, the adaptive immune response of said patient against said cancer. | 08-27-2009 |
20090175892 | Polynucleotides encoding MHC class I-restricted hTERT epitopes, analogues thereof or polyepitopes - This invention relates to the field of anticancer therapy, and to the identification of immunogenic peptides derived from the human telomerase reverse transcriptase (hTERT). The present invention relates to polynucleotides encoding hTERT epitopes restricted to MHC class I molecule, analogues thereof and polyepitopes containing such epitopes and/or analogues. Are also included in the present invention, vector and cell comprising such polynucleotides. The present invention also concerns composition comprising hTERT polypeptides, corresponding polynucleotides, vectors and cells, for use in the treatment and/or prevention of cancer. | 07-09-2009 |
20090131378 | VITAMIN D DERIVATIVES ACTIVE ON THE VITAMIN D NUCLEAR RECEPTOR, PREPARATION AND USES THEREOF - The invention relates to vitamin D derivatives and their uses, particularly in the pharmaceutical industry. The invention discloses compounds having different interesting biological properties, including vitamin D nuclear receptor (VDR) agonist activity, as well as therapeutics methods by administering said compounds, in particular for treating cancer, psoriasis, autoimmune diseases, osteodistrophy and osteoporosis. It further relates to pharmaceutical compositions comprising said compounds and methods for preparing the same. | 05-21-2009 |
20080280318 | Isolation and Culture of a High Purity Population of Cone Photoreceptor Cells by Tissue Dissociation and Pna-Panning, and Biological Applications Thereof - The present invention provides a process and kit for isolating cone photoreceptor cells from retinal tissue with a purity level of at least 80%, typically of about 90%. The isolation process uses a PNA-panning procedure conducted on dissociated retinal tissue. The present invention also provides a culture medium enabling the in vitro survival and development of such isolated cone cells. The means of the invention are applicable to adult mammalian cone cells, and more particularly to adult human cone cells. They have the advantage of being applicable to pathologic or otherwise altered cone cells, and thus give access to the screening of compounds capable of showing neuroprotective activity on adult cone cells. | 11-13-2008 |
20080255039 | Il-15 Binding Site for Il 15-Ralpha and Specific Il-15 Mutants Having Agonists/Antagonists Activity - The present invention relates to the identification of an epitope in human Interleukin-15 (IL-15) that is responsible for binding to the interleukin-15 receptor α-chain. Two IL-15 regions are involved in the formation of this epitope: the first region ( | 10-16-2008 |